HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?

Journal of Hepatology

Volumn 61, Issue 6, 2014, Pages 1430-1433

  Asselah, Tarik ^a   Bruno, Savino ^b   Craxi, Antonio ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Advanced liver disease; Directacting antivirals; Liver function; Portal hypertension

Indexed keywords

DASABUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; TELAPREVIR; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MULTICENTER STUDY (TOPIC); NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; FEMALE; HEPATITIS C, CHRONIC; MALE;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; RIBAVIRIN; RITONAVIR; SULFONAMIDES; URACIL;

EID: 84919654889     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.018     Document Type: Note

References (9)

1. S. Bruno, M.L. Shiffman, S.K. Roberts, E.J. Gane, D. Messinger, and S.J. Hadziyannis Efficacy and safety of peginterferon alfa-2a (40 KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis Hepatology 51 2010 388 397
2. V. Boccaccio, and S. Bruno Management of HCV patients with cirrhosis with direct acting antivirals Liver Int 34 2014 38 45
3. C. Hezode, H. Fontaine, C. Dorival, F. Zoulim, D. Larrey, and V. Canva Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 132 142
4. R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah HCV direct-acting antiviral agents: the best interferon-free combinations Liver Int 34 2014 69 78
5. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, A.W. Lohse, and B. Müllhaupt Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
6. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, and M. Puoti Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
7. J.M. Vierling, S. Zeuzem, F. Poordad, J.P. Bronowicki, M.P. Manns, and B.R. Bacon Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials J Hepatol 61 2014 200 209
8. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, and K. Agarwal ABT 450/r ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1273 1982
9. T. Asselah, S. De Muynck, P. Broet, J. Masliah-Planchon, M. Blanluet, and I. Bieche IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2011 527 532